Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,885 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07452003Recruiting
Immunotherapy plus chemo before and after lung cancer surgery
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07457463Recruiting
Pulmonary fibrosis self-management program
This study tests a learning and self-management program for people with pulmonary fibrosis. It helps you better understand and manage your lung condition.
BernAges 18 years+ - NCT07460154Recruiting
Structured review to improve COPD management
This trial tests a structured review process to help people with COPD who have needed multiple steroid pills in the past year. It aims to improve care and prevent future harm from the condition.
North ShieldsAges 35 years+ - NCT07467863RecruitingPhase 1/Phase 2
Gene-modified immune cells for advanced lung cancer
This trial tests an experimental immune cell therapy (CAR-NK cells) that targets two to three specific markers on your lung cancer cells. It may be an option if your cancer has stopped responding to standard treatments and if tests show your tumor carries those markers.
Shenzhen, GuangdongAges 18–75 - NCT07478809Recruiting
Long-term study of RATIONALE-307 trial participants
This study looks back at people who took part in the RATIONALE-307 trial for a type of lung cancer called squamous non-small cell lung cancer. It aims to learn more about their health outcomes over time by only including those who were still alive when the original trial ended.
BeijingAges Any age - NCT07479277Recruiting
Progel to reduce air leaks after lung surgery
This trial tests whether a special gel (Progel Platinum) can reduce air leaks that sometimes happen after lung cancer surgery. It is for people having minimally invasive surgery to remove the upper or lower lobe of the lung.
Candiolo, TorinoAges 18–99 - NCT07483112Recruiting
Fiber supplement study for advanced lung cancer patients
This trial tests whether adding a fiber supplement to standard immunotherapy can help treat advanced non-small cell lung cancer. It's for people whose tumors have high PD-L1 levels and no treatable genetic mutations.
BaselAges 18 years+ - NCT07485452RecruitingPhase 2
Boosting osimertinib's reach to the brain
This trial tests whether adding febuxostat helps the lung cancer drug osimertinib get into the brain better. It is for people with EGFR-mutated NSCLC who are already taking osimertinib, regardless of whether their cancer is stable or slowly progressing.
AmsterdamAges 18 years+ - NCT07285655RecruitingPhase 3
Study of L606 for lung disease with high blood pressure in the lungs
This trial tests a new treatment called L606 for people who have both a type of lung disease (ILD) and high blood pressure in the lungs (PH). The goal is to see if it is safe and helps with exercise and breathing.
Scottsdale, ArizonaAges 18–80 - NCT06747585RecruitingPhase 1/Phase 2
ALE.P02 for advanced squamous cell cancers with CLDN1
This trial tests a new drug called ALE.P02 for people with advanced squamous cell cancers (like lung, head and neck, esophagus, or skin cancer) that have a certain protein called CLDN1. The drug is given alone and aims to shrink or stop the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Fort Smith, ArkansasAges 18 years+ - NCT07673861Recruiting
Using ctDNA to find resistance and guide cancer treatment
This trial uses a simple blood test to look for changes in your cancer's DNA that might show why your current treatment stopped working. The results could help your doctor choose your next treatment more precisely.
LondonAges 18 years+ - NCT07487064Recruiting
Treating lung tumors with pulsed electric field before surgery
This study tests a new device that uses brief electrical pulses (pulsed electric field or PEF) to treat lung tumors before they are surgically removed. The goal is to see if this approach can be safely added to standard lung cancer surgery.
ShatinAges 18 years+ - NCT07490041RecruitingEarly Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Hangzhou, ZhejiangAges 5 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07504367Recruiting
AI assistance in tumor treatment meetings
This study tests whether a large language model can help doctors make better decisions in tumor multidisciplinary team meetings. It evaluates junior doctors with specific experience levels.
Guangzhou, GuangdongAges 25–33 - NCT07510321Recruiting
A study of FL-261 imaging for cancer diagnosis
This trial tests a new imaging agent called FL-261 to help doctors see and stage cancers more clearly. If you have a known or suspected cancer like lung, colon, or head and neck cancer, this study may improve how your cancer is evaluated.
Wuhan, HubeiAges 18 years+ - NCT07511933Recruiting
New PET scan to detect tumor regrowth vs. scar tissue in brain
This study tests a new type of PET scan (a special imaging test) that uses a radioactive tracer to help doctors tell the difference between scar tissue from past radiation and cancer that has come back in the brain. This could help avoid unnecessary surgery or additional treatment.
AmsterdamAges Any age - NCT07514481Recruiting
Lung ultrasound comparison of two surfactant delivery methods in preterm babies
This study compares two ways of giving surfactant (a lung-coating medicine) to newborns with breathing trouble: LISA (a gentler, less invasive method) versus traditional breathing tube delivery. Researchers will use ultrasound to see how the medicine spreads in each baby's lungs to find the best approach.
DohaAges 6 months–10 months - NCT07517393Recruiting
Creating a Digital Lung Model Using AI and CT Scans
This study collects information from your chest CT scans and medical history to build an artificial intelligence model of how your lungs work. This 'digital twin' may help doctors better understand and predict lung health in the future.
Peschiera del Garda, VeronaAges 18 years+ - NCT07519655RecruitingPhase 1
New Cancer Drug Treatment for Advanced Lung, Esophageal, or Skin Cancer
This study tests a new drug called PF-08046033 in people with advanced lung cancer (NSCLC), esophageal cancer (ESCC), or melanoma (skin cancer) that has spread or can't be surgically removed. The drug targets a specific protein to help slow or stop cancer growth.
Denver, ColoradoAges 18 years+ - NCT07524114Recruiting
Tracking cancer recurrence risk after treatment
This study uses advanced blood tests to detect tiny amounts of cancer DNA after you've completed cancer treatment. The goal is to catch any signs of cancer coming back as early as possible, which may help doctors intervene sooner.
Toronto, OntarioAges 18 years+
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,885 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.